Autolus Therapeutics is a clinical-stage biopharmaceutical firm based in London that develops engineered T cell treatments for cancer and autoimmune conditions. The company's pipeline includes AUCATZYL, an approved cell therapy using modified immune cells targeting CD19, along with multiple investigational programs in early to mid-stage testing for conditions such as leukemia, lymphoma, multiple myeloma, lupus, and neurological cancers.

entry readiness 50 · MODERATE · exit proximity 0

Value area 1.37–2.10 · 36% of 120d volume overhead · moderate overhead